FOXO1 and hyperlipidemia: Altogether, TPP-HT simultaneously suppresses the activation of p38 MAPK induced by PA and activates FoxO1 and Nrf2, which together combats oxidative stress and inflammation in hyperlipidemia-associated endothelial dysfunction.